Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

rebel distributors corp - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 300 mg - zidovudine tablets, a nucleoside reverse transcriptase inhibitor, are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. zidovudine tablets are indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.2)].  the indication is based on a dosing regimen that included 3 components:   - antepartum therapy of hiv-1 infected mothers - intrapartum therapy of hiv-1 infected mothers - post-partum therapy of hiv-1 exposed neonate. points to consider prior to initiating zidovudine tablets in pregnant women for the prevention of maternal-fetal hiv-1 transmission include:   - in most cases, zidovudine tablets for prevention of maternal-fetal hiv-1 transmission should be given in combination with other antiretroviral drugs. - prevention of hiv-1 transmission in women who have received zidovudine tablets for a prolonged period before pregnancy has not been evaluated. - because the fetus is most susceptible to the potential teratogenic eff

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

cipla ltd. - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 100 mg - zidovudine, a nucleoside reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. zidovudine is indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.3)] . the indication is based on a dosing regimen that included 3 components: - antepartum therapy of hiv-1-infected mothers - intrapartum therapy of hiv-1-infected mothers - post-partum therapy of hiv-1-exposed neonate points to consider prior to initiating zidovudine in pregnant women for the prevention of maternal-fetal hiv-1 transmission include: - in most cases, zidovudine for prevention of maternal-fetal hiv-1 transmission should be given in combination with other antiretroviral drugs. - prevention of hiv-1 transmission in women who have received zidovudine for a prolonged period before pregnancy has not been evaluated. - because the fetus is most susceptible to the potential teratogenic effects of drugs dur

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

acetris health, llc - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 300 mg - zidovudine tablets, a nucleoside reverse transcriptase inhibitor, are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. zidovudine tablets are indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.3)]. the indication is based on a dosing regimen that included 3 components: 1. antepartum therapy of hiv-1-infected mothers 2. intrapartum therapy of hiv-1-infected mothers 3. post-partum therapy of hiv-1-exposed neonate points to consider prior to initiating zidovudine tablets in pregnant women for the prevention of maternal-fetal hiv-1 transmission include: • in most cases, zidovudine tablets for prevention of maternal-fetal hiv-1 transmission should be given in combination with other antiretroviral drugs. • prevention of hiv-1 transmission in women who have received zidovudine tablets for a prolonged period before pregnancy has not been evaluated. • because the fetus is most susceptible to the potential teratogen

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

state of florida doh central pharmacy - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 300 mg - zidovudine, a nucleoside reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. zidovudine tablets are indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.2)]. the indication is based on a dosing regimen that included three components: - antepartum therapy of hiv-1 infected mothers - intrapartum therapy of hiv-1 infected mothers - post-partum therapy of hiv-1 exposed neonate. points to consider prior to initiating zidovudine tablets in pregnant women for the prevention of maternal-fetal hiv-1 transmission include: - in most cases, zidovudine tablets for prevention of maternal-fetal hiv-1 transmission should be given in combination with other antiretroviral drugs. - prevention of hiv-1 transmission in women who have received zidovudine tablets for a prolonged period before pregnancy has not been evaluated. - because the fetus is most susceptible to the potential teratogenic effects of d

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

doh central pharmacy - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 300 mg - zidovudine tablets, a nucleoside reverse transcriptase inhibitor, are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. zidovudine tablets are indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.2)].  the indication is based on a dosing regimen that included 3 components:   - antepartum therapy of hiv-1 infected mothers - intrapartum therapy of hiv-1 infected mothers - post-partum therapy of hiv-1 exposed neonate. points to consider prior to initiating zidovudine tablets in pregnant women for the prevention of maternal-fetal hiv-1 transmission include:   - in most cases, zidovudine tablets for prevention of maternal-fetal hiv-1 transmission should be given in combination with other antiretroviral drugs. - prevention of hiv-1 transmission in women who have received zidovudine tablets for a prolonged period before pregnancy has not been evaluated. - because the fetus is most susceptible to the potential teratogenic

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

acetris health, llc - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 100 mg - zidovudine capsules , a nucleoside reverse transcriptase inhibitor, are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. zidovudine capsules are indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.3)]. the indication is based on a dosing regimen that included 3 components: - antepartum therapy of hiv-1-infected mothers - intrapartum therapy of hiv-1-infected mothers - post-partum therapy of hiv-1-exposed neonate points to consider prior to initiating zidovudine capsules in pregnant women for the prevention of maternal-fetal hiv-1 transmission include: - in most cases, zidovudine capsules for prevention of maternal-fetal hiv-1 transmission should be given in combination with other antiretroviral drugs. - prevention of hiv-1 transmission in women who have received zidovudine capsules for a prolonged period before pregnancy has not been evaluated. - because the fetus is most susceptible to the potential teratoge

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

viiv healthcare company - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 100 mg - retrovir, a nucleoside reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. retrovir is indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.3)]. the indication is based on a dosing regimen that included 3 components: points to consider prior to initiating retrovir in pregnant women for the prevention of maternal-fetal hiv-1 transmission include: retrovir is contraindicated in patients who have had a potentially life-threatening hypersensitivity reaction (e.g., anaphylaxis, stevens-johnson syndrome) to any of the components of the formulations. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to retrovir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the o

Malta - angļu - Malta Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - zidovudine, lamivudine - film-coated tablet - zidovudine 300 milligram(s) ; lamivudine 150 milligram(s) - antivirals for systemic use

Malta - angļu - Malta Medicines Authority

mylan pharmaceuticals limited damastown industrial park mulhuddart dublin15 dublin, ireland - zidovudine, lamivudine - film-coated tablet - zidovudine 300 mg lamivudine 150 mg - antivirals for systemic use

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lamivudine, quantity: 150 mg; zidovudine, quantity: 300 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; propylene glycol; magnesium stearate; sodium starch glycollate type a; titanium dioxide; hypromellose - lamivudine and zidovudine combination tablet is indicated for use alone or in combination with other antiretroviral therapies in the treatment of hiv infection.